140 related articles for article (PubMed ID: 12960748)
1. Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients.
Inada T; Senoo H; Iijima Y; Yamauchi T; Yagi G
Psychiatr Genet; 2003 Sep; 13(3):163-8. PubMed ID: 12960748
[TBL] [Abstract][Full Text] [Related]
2. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
Plesnicar BK; Zalar B; Breskvar K; Dolzan V
J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
[TBL] [Abstract][Full Text] [Related]
3. Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy.
Crescenti A; Mas S; Gassó P; Parellada E; Bernardo M; Lafuente A
Clin Exp Pharmacol Physiol; 2008 Jul; 35(7):807-11. PubMed ID: 18346175
[TBL] [Abstract][Full Text] [Related]
4. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients.
Scordo MG; Spina E; Romeo P; Dahl ML; Bertilsson L; Johansson I; Sjöqvist F
Eur J Clin Pharmacol; 2000 Dec; 56(9-10):679-83. PubMed ID: 11214775
[TBL] [Abstract][Full Text] [Related]
5. Risperidone plasma levels, clinical response and side-effects.
Riedel M; Schwarz MJ; Strassnig M; Spellmann I; Müller-Arends A; Weber K; Zach J; Müller N; Möller HJ
Eur Arch Psychiatry Clin Neurosci; 2005 Aug; 255(4):261-8. PubMed ID: 15565299
[TBL] [Abstract][Full Text] [Related]
6. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype.
Jaanson P; Marandi T; Kiivet RA; Vasar V; Vään S; Svensson JO; Dahl ML
Psychopharmacology (Berl); 2002 Jun; 162(1):67-73. PubMed ID: 12107620
[TBL] [Abstract][Full Text] [Related]
7. CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects.
Ivanova SA; Filipenko ML; Vyalova NM; Voronina EN; Pozhidaev IV; Osmanova DZ; Ivanov MV; Fedorenko OY; Semke AV; Bokhan NA
Bull Exp Biol Med; 2016 Mar; 160(5):687-90. PubMed ID: 27021090
[TBL] [Abstract][Full Text] [Related]
8. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients.
Fu Y; Fan CH; Deng HH; Hu SH; Lv DP; Li LH; Wang JJ; Lu XQ
Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia.
Kapitany T; Meszaros K; Lenzinger E; Schindler SD; Barnas C; Fuchs K; Sieghart W; Aschauer HN; Kasper S
Schizophr Res; 1998 Jul; 32(2):101-6. PubMed ID: 9713905
[TBL] [Abstract][Full Text] [Related]
10. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study.
Kobylecki CJ; Jakobsen KD; Hansen T; Jakobsen IV; Rasmussen HB; Werge T
Neuropsychobiology; 2009; 59(4):222-6. PubMed ID: 19521114
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients.
Liou YJ; Wang YC; Bai YM; Lin CC; Yu SC; Liao DL; Lin MW; Chen JY; Lai IC
Neuropsychobiology; 2004; 49(4):167-73. PubMed ID: 15118351
[TBL] [Abstract][Full Text] [Related]
12. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients.
Andreassen OA; MacEwan T; Gulbrandsen AK; McCreadie RG; Steen VM
Psychopharmacology (Berl); 1997 May; 131(2):174-9. PubMed ID: 9201806
[TBL] [Abstract][Full Text] [Related]
13. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients.
Lohmann PL; Bagli M; Krauss H; Müller DJ; Schulze TG; Fangerau H; Ludwig M; Barkow K; Held T; Heun R; Maier W; Rietschel M; Rao ML
Pharmacopsychiatry; 2003; 36(2):73-8. PubMed ID: 12734765
[TBL] [Abstract][Full Text] [Related]
14. Lack of association between debrisoquine 4-hydroxylase (CYP2D6) gene polymorphisms and schizophrenia.
Jönsson EG; Dahl ML; Roh HK; Jerling M; Sedvall GC
Psychiatr Genet; 1998; 8(1):25-8. PubMed ID: 9564684
[TBL] [Abstract][Full Text] [Related]
15. The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol.
Zivković M; Mihaljević-Peles A; Bozina N; Sagud M; Nikolac-Perkovic M; Vuksan-Cusa B; Muck-Seler D
J Clin Psychopharmacol; 2013 Oct; 33(5):593-9. PubMed ID: 23963056
[TBL] [Abstract][Full Text] [Related]
16. Association between neuroleptic drug-induced extrapyramidal symptoms and dopamine D2-receptor polymorphisms in Japanese schizophrenic patients.
Nakazono Y; Abe H; Murakami H; Koyabu N; Isaka Y; Nemoto Y; Murata S; Tsutsumi Y; Ohtani H; Sawada Y
Int J Clin Pharmacol Ther; 2005 Apr; 43(4):163-71. PubMed ID: 15966462
[TBL] [Abstract][Full Text] [Related]
17. Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients.
Gunes A; Dahl ML; Spina E; Scordo MG
Eur J Clin Pharmacol; 2008 May; 64(5):477-82. PubMed ID: 18205001
[TBL] [Abstract][Full Text] [Related]
18. 1846G>A polymorphism of CYP2D6 gene and extrapyramidal side effects during antipsychotic therapy among Russians and Tatars: a pilot study.
Sychev DA; Burashnikova IS; Kazakov RE
Drug Metab Pers Ther; 2016 Dec; 31(4):205-212. PubMed ID: 27875318
[TBL] [Abstract][Full Text] [Related]
19. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics.
Ohmori O; Suzuki T; Kojima H; Shinkai T; Terao T; Mita T; Abe K
Schizophr Res; 1998 Jul; 32(2):107-13. PubMed ID: 9713906
[TBL] [Abstract][Full Text] [Related]
20. [Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism].
Reggiani K; Vandel P; Haffen E; Sechter D; Bizouard P; Vandel S
Encephale; 2000; 26(1):62-7. PubMed ID: 10875063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]